4 HealthTech Stocks Trending Now NARI stock, MMSI stock, CVRX stock, INCY stock
Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at finmarketnews.com, will continue to monitor these healthtech companies to see if the momentum continues. FinMarketNews.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent NARI Stock Price: $41.60
Summary: Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. Its initial product offering comprises 2 minimally-invasive, novel catheter-based mechanical thrombectomy devices. It built its products purposely on the basis of the specific characteristics of the venous system and the treatment of the two distinct indications of venous thromboembolism or VTE (deep vein thrombosis and pulmonary embolism/ PE). Its FlowTriever product is the first thrombectomy system, which is FDA-cleared, used for the treatment of PE. Its advanced systems & processes to control the key relationships between its sales representatives and treating physicians like cardiologists, radiologists, helps it to quickly iterate products, launch and execute physician education and training programs and scale its sales organization. The company markets and sells its products to hospitals across the U.S.
Richard Newitter analyst at Truist Financial reiterates coverage on Inari Medical, Inc. (NARI) stock in the energy sector with a Hold rating and has set NARI's stock price target at $47.
TipRanks.com reports that Inari Medical, Inc. currently has 4 analysts offering 12-month price targets on NARI and the consensus is a Buy rating with an average stock price target of $59.00. The most recent NARI stock price we have is $41.60 and we are not making any NARI forecasts at this time.
In addition, TradingView issued a rating for NARI over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on NARI. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on NARI, please click here >>
Merit Medical Systems, Inc., MMSI
Recent MMSI Stock Price: $76.63
Summary: Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company offers products focused in five core product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, cardiovascular and critical care as well as endoscopy. However, the company operates in two revenue segments: Cardiovascular and Endoscopy Devices.
Michael Petusky analyst at Barrington reiterates coverage on Merit Medical Systems, Inc. (MMSI) stock in the energy sector with a Buy rating and has set MMSI's stock price target at $100.
TipRanks.com reports that Merit Medical Systems, Inc. currently has 4 analysts offering 12-month price targets on MMSI and the consensus is a Buy rating with an average stock price target of $96.00. The most recent MMSI stock price we have is $76.63 and we are not making any MMSI forecasts at this time.
In addition, TradingView issued a rating for MMSI over the next month, Barchart.com has a buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on MMSI. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MMSI, please click here >>
CVRx, Inc., CVRX
Recent CVRX Stock Price: $10.12
Summary: CVRx Inc. is a commercial-stage medical device company. It focused on developing, manufacturing and commercializing neuromodulation solutions for patients with cardiovascular diseases. CVRx Inc. is headquartered in Minneapolis, MN.
Robbie Marcus analyst at J.P. Morgan reiterates coverage on CVRx, Inc. (CVRX) stock in the energy sector with a Hold rating and has set CVRX's stock price target at $13.
TipRanks.com reports that CVRx, Inc. currently has 4 analysts offering 12-month price targets on CVRX and the consensus is a Buy rating with an average stock price target of $17.25. The most recent CVRX stock price we have is $10.12 and we are not making any CVRX forecasts at this time.
In addition, TradingView issued a rating for CVRX over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on CVRX. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CVRX, please click here >>
Incyte Corporation, INCY
Recent INCY Stock Price: $52.94
Summary: Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.
Marc Frahm analyst at TD Cowen reiterates coverage on Incyte Corporation (INCY) stock in the energy sector with a Buy rating and has set INCY's stock price target at $80.
TipRanks.com reports that Incyte Corporation currently has 3 analysts offering 12-month price targets on INCY and the consensus is a Buy rating with an average stock price target of $72.00. The most recent INCY stock price we have is $52.94 and we are not making any INCY forecasts at this time.
In addition, TradingView issued a rating for INCY over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a n/a short-term outlook. Remember, securities are volatile, so please do your own research on INCY. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on INCY, please click here >>
The editors at finmarketnews.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinMarketNews.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinMarketNews.com.
==============================================================================